Medical Treatment for Pain in Parkinson's Disease

doi:10.12114/j.issn.1007-9572.2019.00.241

Abstract

Abstract: Pain is a common non-motor symptom of Parkinson's disease（PD），with its prevalence ranging from 40% to 85%.PD patients with pain are more likely to complicated with other non-motor symptoms，which cause decrease in patients' quality of life.This article summarized the clinical reports of drug therapy for patients with Parkinson's pain and its possible mechanism of action.The aim of this paper was to provide clinicians with reference information for the treatment of patients in pain with Parkinson's disease and put forward new goals to improve the treatment standard for the disease pain.

Key words: Parkinson's disease, Pain, Medication, Review, Clinical practice

摘要： 疼痛是帕金森病患者常见的一种非运动症状，患病率从40％~85％不等，疼痛的患者更容易合并其他非运动症状，导致患者的生活质量下降。本文归纳总结了帕金森病疼痛患者药物治疗的临床报道和其可能的作用机制，旨在为临床医生治疗帕金森病疼痛患者提供具有指导价值的参考信息，同时为完善帕金森病疼痛诊疗规范提出新的
目标。

关键词: 帕金森病, 疼痛, 药物治疗, 综述, 临床实践

SHEN Yalian,CHENG Oumei. Medical Treatment for Pain in Parkinson's Disease　[J]. Chinese General Practice, 2019, 22(16): 2008-2014. DOI: 10.12114/j.issn.1007-9572.2019.00.241.
申雅恋,承欧梅. 帕金森病疼痛的药物治疗[J]. 中国全科医学, 2019, 22(16): 2008-2014. DOI: 10.12114/j.issn.1007-9572.2019.00.241.

References

［1］BROEN P G，BRAAKSMA M，PATIJN J，et al．Prevalence of pain in Parkinson's disease：a systematic review using the modified QUADAS tool［J］．Movement Disorders Official Journal of the Movement Disorder Society，2012，27（4）：480．DOI：10.1002/mds.24054.
［2］VALKOVIC P，MINAR M，SINGLIAROVA H，et al．Pain in Parkinson's disease：a cross-sectional study of its prevalence，types，and relationship to depression and quality of life［J］．PLoS One，2015，10（8）：e0136541．DOI：10.1371/journal.pone.0136541.
［3］NèGREPAGèS L，REGRAGUI W，BOUHASSIRA D，et al．Chronic pain in Parkinson's disease：the cross-sectional French DoPaMiP survey［J］．Movement Disorders，2008，23（10）：1361-1369．DOI：10.1002/mds.22142.
［4］THOMPSON T，GALLOP K，CORRELL C U，et al．Pain perception in Parkinson's disease：a systematic review and meta-analysis of experimental studies［J］．Ageing Research Reviews，2017，35：74-86．DOI：10.1016/j.arr.2017.01.005.
［5］CHUDLER E H，DONG W K.The role of the basal ganglia in nociception and pain［J］．Pain，1995，60（1）：3-38．DOI：10.1016/0304-3959（94）00172-B.
［6］BORSOOK D，UPADHYAY J，CHUDLER E H，et al．A key role of the basal ganglia in pain and analgesia-insights gained through human functional imaging［J］．Molecular Pain，2010，6（1）：27．DOI：10.1186/1744-8069-6-27.
［7］BEISKE A G，LOGE J H，R?NNINGEN A，et al．Pain in Parkinson's disease：prevalence and characteristics［J］．Pain，2009，141（1/2）：173-177.
［8］FORD B.Pain in Parkinson's disease［J］．Movement Disorders，2010，25（4）：507-508．DOI：10.1002/mds.22716.
［9］WASNER G，DEUSCHL G.Pains in Parkinson disease：many syndromes under one umbrella［J］．Nature Reviews Neurology，2012，8（5）：284-294．DOI：10.1038/nrneurol.2012.54.
［10］CHAUDHURI K R，SCHAPIRA A H.Non-motor symptoms of Parkinson's disease：dopaminergic pathophysiology and treatment［J］．Lancet Neurology，2009，8（5）：464-474．DOI：10.1016/S1474-4422（09）70068-7.
［11］NEBE A，EBERSBACH G.Pain intensity on and off levodopa in patients with Parkinson's disease［J］．Movement Disorders Official Journal of the Movement Disorder Society，2010，24（8）：1233-1237．DOI：10.1002/mds.22546.
［12］STACY M.The wearing-off phenomenon and the use of questionnaires to facilitate its recognition in Parkinson's disease［J］．Journal of Neural Transmission，2010，117（7）：837．DOI：10.1007/s00702-010-0424-5.
［13］CURY R G，GALHARDONI R，FONOFF E T，et al．Sensory abnormalities and pain in Parkinson disease and its modulation by treatment of motor symptoms［J］．European Journal of Pain，2016，20（2）：151．DOI：10.1002/ejp.745.
［14］GEROIN C，GANDOLFI M，BRUNO V，et al．Integrated approach for pain management in Parkinson disease［J］．Current Neurology & Neuroscience Reports，2016，16（4）：28．DOI：10.1007/s11910-016-0628-7.
［15］GERDELAT-MAS A，SIMONETTA-MOREAU M，THALAMAS C，et al．Levodopa raises objective pain threshold in Parkinson's disease：a RⅢ reflex study［J］．Journal of Neurology Neurosurgery & Psychiatry，2007，78（10）：1140-1142．DOI：10.1136/jnnp.2007.120212.
［16］QUINN N P，LANG A E，KOLLER W C，et al．Painful Parkinson's disease［J］．Lancet，1986，327（8494）：1366．DOI：10.1016/S0140-6736（86）91674-0.
［17］FORD B，LOUIS E D，GREENE P，et al．Oral and genital pain syndromes in Parkinson's disease［J］．Movement Disorders Official Journal of the Movement Disorder Society，1996，11（4）：421-426．DOI：10.1002/mds.870110411.
［18］COON E A，LAUGHLIN R S.Burning mouth syndrome in Parkinson's disease：dopamine as cure or cause?［J］．Journal of Headache & Pain，2012，13（8）：687．DOI：10.1007/s10194-012-0421-1.
［19］FABBRI M，COELHO M，GUEDES L C，et al．Response of non-motor symptoms to levodopa in late-stage Parkinson's disease：results of a levodopa challenge test［J］．Parkinsonism & Related Disorders，2017，39：37．DOI：10.1016/j.parkreldis.2017.02.007.
［20］KARLSBORG M，KORBO L，REGEUR L，et al．Duodopa pump treatment in patients with advanced Parkinson's disease［J］．Ugeskrift for Laeger，2010，172（23）：1745．
［21］HONIG H，ANTONINI A，MARTINEZ-MARTIN P，et al．
Intrajejunal levodopa infusion in Parkinson's disease：a pilot multicenter study of effects on nonmotor symptoms and quality of life［J］．Movement Disorders Official Journal of the Movement Disorder Society，2009，24（10）：1468．DOI：10.1002/mds.22596.
［22］WANG Y，SUN S G，ZHU S Q，et al．Analysis of pramipexole dose–response relationships in Parkinson's disease［J］．Drug Design Development & Therapy，2017，11：83-89．DOI：10.2147/DDDT.S112723.
［23］PANDEY S，JAIN S.Pramipexole-associated fixed limb dystonia in Parkinson's disease［J］．Parkinsonism & Related Disorders，2016，31：159-160．DOI：10.1016/j.parkreldis.2016.08.018.
［24］MIRANDA M，CHANá P.Severe off-period facial dystonia in Parkinson's disease［J］．Movement Disorders Official Journal of the Movement Disorder Society，2000，15（1）：163-164．
［25］FACTOR S A.Literature review：intermittent subcutaneous apomorphine therapy in Parkinson's disease［J］．Neurology，2004，62（4）：12-17．DOI：10.1212/WNL.62.6_suppl_4.S12.
［26］LETVINENKO I V，ODINAK M M，MOGIL N V.Pain and depression in Parkinson's disease：new therapeutic possibilities of pramipexole［J］．Zh Nevrol Psikhiatr Im S S Korsakova，2008，108（11）：36-38.
［27］STUGINSKI-BARBOSA J，RODRIGUES G G，BIGAL M E，et al．Burning mouth syndrome responsive to pramipexol［J］．Journal of Headache & Pain，2008，9（1）：43-45．DOI：10.1007/s10194-008-0003-4.
［28］BARONE P，POEWE W，ALBRECHT S，et al．Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease：a randomised，double-blind，placebo-controlled trial［J］．Lancet Neurology，2010，9（6）：556-567．DOI：10.1016/S1474-4422（10）70106-X.
［29］TRENKWALDER C，KIES B，RUDZINSKA M，et al．Rotigotine effects on early morning motor function and sleep in Parkinson's disease：a double-blind，randomized，placebo-controlled study（RECOVER）［J］．Movement Disorders Official Journal of the Movement Disorder Society，2011，26（1）：90-99．DOI：10.1002/mds.23441.
［30］VALLDERIOLA F，COMPTA Y，APARICIO J，et al．Effects of night-time use of rotigotine on nocturnal symptoms in Parkinson's disease［J］．Parkinson's Disease，2015，21（8）：1-6．DOI：10.1155/ 2015/475630.
［31］WOITALLA D，KASSUBEK J，TIMMERMANN L，et al．Reduction of gastrointestinal symptoms in Parkinson's disease after a switch from oral therapy to rotigotine transdermal patch：a non-interventional prospective multicenter trial［J］．Parkinsonism Relat Disord，2015，21（3）：199-204．DOI：10.1016/j.parkreldis.2014.11.024.
［32］ROMAIN L，LUCILE B，JACQUES S，et al．Acute genital pain during non-motor fluctuations improved by apomorphine［J］．Movement Disorders Official Journal of the Movement Disorder Society，2013，28（5）：687-688．DOI：10.1002/mds.25379.
［33］RASCOL O，ZESIEWICZ T，CHAUDHURI K R，et al．A randomized controlled exploratory pilot study to evaluate the effect of rotigotine transdermal patch on Parkinson's disease–associated chronic pain［J］．Journal of Clinical Pharmacology，2016，56（7）：852．DOI：10.1002/jcph.678.
［34］PARK D.Pramipexole-induced limb dystonia and its associated complex regional pain syndrome in idiopathic Parkinson's disease：a case report［J］．Medicine，2017，96（28）：e7530．DOI：10.1097/MD.0000000000007530.
［35］BUNTEN S，HAPPE S.Rotigotine transdermal system：a short review［J］．Neuropsychiatr Dis Treat，2006，2（4）：421-426．DOI：10.2147/nedt.2006.2.4.421.
［36］SCHELLER D，ULLMER C，BERKELS R，et al．The in vitro receptor profile of rotigotine：a new agent for the treatment of Parkinson's disease［J］．Naunyn Schmiedebergs Arch Pharmacol，2009，379（1）：73-86．DOI：10.1007/s00210-008-0341-4.
［37］KASSUBEK J，CHAUDHURI K R，ZESIEWICZ T，et al．Rotigotine transdermal system and evaluation of pain in patients with Parkinson's disease：a post hoc analysis of the RECOVER study［J］．BMC Neurology，2014，14（1）：42．DOI：10.1186/1471-2377-14-42.
［38］GIANLUIGIGESSA G.Apomorphine and other dopaminomimetics［M］．New York：Raven Press，1981.
［39］CATTANEO C，BARONE P，BONIZZONI E，et al．Effects of safinamide on pain in fluctuating Parkinson's disease patients：a post-hoc analysis［J］．Journal of Parkinsons Disease，2017，7（1）：95．DOI：10.3233/JPD-160911.
［40］TANEJA A，PASQUA O D，DANHOF M.Challenges in translational drug research in neuropathic and inflammatory pain：the prerequisites for a new paradigm［J］．European Journal of Clinical Pharmacology，2017，73（10）：1219-1236．DOI：10.1007/s00228-017-2301-8.
［41］DELLAPINA E.Emerging analgesic drugs for Parkinson's disease［J］．Expert Opin Emerg Drugs，2012，17（2）：157-171.
［42］TAKAHASHI T，TAMURA M，OSABE K，et al．A rare case of Parkinson's disease with severe neck pain owing to crowned dens syndrome［J］．Case Reports in Neurology，2014，6（2）：149-155．DOI：10.1159/000362514.
［43］TOMAZONI S S，FRIGO L，FERREIRA T C，et al．Effects of photobiomodulation therapy and topical non-steroidal anti-inflammatory drug on skeletal muscle injury induced by contusion in rats—part 1：morphological and functional aspects［J］．Lasers in Medical Science，2017，32（8）：1-10．DOI：10.1007/s10103-017-2346-z.
［44］BUHMANN C，WROBEL N，GRASHORN W，et al．Pain in Parkinson disease：a cross-sectional survey of its prevalence，specifics，and therapy［J］．Journal of Neurology，2017，264（4）：758-769．DOI：10.1007/s00415-017-8426-y.
［45］YUST K S，HERSHKOVITZ R，GUREVICH T，et al．Pain in extrapyramidal neurodegenerative diseases［J］．Clinical Journal of Pain，2016，33（7）：635．DOI：10.1097 /AJP.0000000000000437.
［46］ROGAWSKI M A，L?SCHER W.The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions［J］．Nature Medicine，2004，6：685-692．DOI：10.1038/nrn1430.
［47］IWASAKI Y，IKEDA K，SHIOJIMA T，et al．Increased plasma concentrations of aspartate，glutamate and glycine in Parkinson's disease［J］．Neuroscience Letters，1992，145（2）：175-177．DOI：10.1016/0304-3940（92）90015-Y.
［48］LEE H H，DEEB T Z，WALKER J A，et al．NMDA receptor activity downregulates KCC2 resulting in depolarizing GABAA receptor mediated currents［J］．Channels，2011，14（6）：736-743．DOI：10.4161/chan.5.6.17952.
［49］SIDHU H S，SADHOTRA A.Current status of the new antiepileptic drugs in chronic pain［J］．Frontiers in Pharmacology，2016，7（45）：276．DOI：10.3389/fphar.2016.00276.
［50］SAVAGE N W.Burning mouth syndrome：patient management［J］．Australian Dental Journal，1996，41（6）：363-366.
［51］MO X，ZHANG J，FAN Y，et al．Thermal and mechanical quantitative sensory testing in Chinese patients with burning mouth syndrome：a probable neuropathic pain condition?［J］．Journal of Headache & Pain，2015，16（1）：84．DOI：10.1186/s10194-015-0565-x.
［52］HAGELBERG N，FORSSELL H，AALTO S，et al．Altered dopamine D2 receptor binding in atypical facial pain［J］．Pain，2003，106（1）：43-48．DOI：10.1016/s0304-3959（03）00275-6.
［53］LóPEZ-D'ALESSANDRO E，ESCOVICH L.Combination of alpha lipoic acid and gabapentin，its efficacy in the treatment of burning mouth syndrome：a randomized，double-blind，placebo controlled trial［J］．Medicina Oral Patología Oral Y Cirugía Bucaledinglesa，2011，16（5）：e635-640．DOI：10.4317/medoral.16942.
［54］WHITE T L，KENT P F，KURTZ D B，et al．Effectiveness of gabapentin for treatment of burning mouth syndrome［J］．Archives of Otolaryngology-Head and Neck Surgery，2004，130（6）：786-788．DOI：10.1001/archotol.130.6.786.
［55］HECKMANN S M，HECKMANN J G，UNGETHüM A，et al．Gabapentin has little or no effect in the treatment of burning mouth syndrome-results of an open-label pilot study［J］．European Journal of Neurology，2006，13（7）：e6-7．DOI：10.1111/j.1468-1331.2006.01294.x.
［56］UKAI K，FUJISHIRO H，OZAKI N.Effectiveness of low-dose pregabalin in three patients with Lewy body disease and central neuropathic pain［J］．Psychogeriatrics，2016，17（2）：115．DOI：10.1111/psyg.12192.
［57］ABE K，CHIBA Y，KATSUSE O，et al．A case of Parkinson disease with both visual hallucination and pain improved by gabapentin［J］．Clinical Neuropharmacology，2016，39（1）：55-56．DOI：10.1097/wnf.0000000000000122.
［58］LI C，SUGAM J A，LOWERYGIONTA E G，et al．Mu opioid receptor modulation of dopamine neurons in the periaqueductal gray/dorsal raphe：a role in regulation of pain［J］．Neuropsychopharmacology Official Publication of the American College of Neuropsychopharmacology，2016，41（8）：2122．DOI：10.1038 /npp.2016.12.
［59］TOBALDINI G，REIS R A，SARDI N F，et al．Dopaminergic mechanisms in periaqueductal gray-mediated antinociception［J］．Behavioural Pharmacology，2018，29（1）：225-233．DOI：10.1097/FBP.0000000000000346.
［60］MARTíNRUIZ R，UGEDO L，HONRUBIA M A，et al．Control of serotonergic neurons in rat brain by dopaminergic receptors outside the dorsal raphe nucleus［J］．Journal of Neurochemistry，2001，77（3）：762-775．DOI：10.1046/j.1471-4159.2001.00275.x.
［61］MADEO G，SCHIRINZI T，NATOLI S，et al．Efficacy and safety profile of prolonged release oxycodone in combination with naloxone（OXN PR）in Parkinson's disease patients with chronic pain［J］．Journal of Neurology，2015，262（9）：2164-2170．DOI：10.1007/s00415-015-7823-3.
［62］POELAERT J，KOOPMANSKLEIN G，DIOH A，et al．Treatment with prolonged-release oxycodone/naloxone improves pain relief and opioid-induced constipation compared with prolonged-release oxycodone in patients with chronic severe pain and laxative-refractory constipation［J］．Clinical Therapeutics，2015，37（4）：784-792．DOI：10.1016/j.clinthera.2015.02.010.
［63］TRENKWALDER C，CHAUDHURI K R，MARTINEZ-MARTIN P，et al．Prolonged-release oxycodone-naloxone for treatment of severe pain in patients with Parkinson's disease（PANDA）：a double-blind，randomised，placebo-controlled trial［J］．Lancet Neurology，2015，14（12）：1161．DOI：10.1016/S1474-4422（15）00243-4.
［64］CIRCUITRY I.Central nervous system mechanisms of pain modulation［J］．Txetbook of Pain，2006，2（6）：44-46．DOI：10.1016/B0-443-07287-6/50012-6.
［65］WANG C T，MAO C J，ZHANG X Q，et al．Attenuation of hyperalgesia responses via the modulation of 5-hydroxytryptamine signalings in the rostral ventromedial medulla and spinal cord in a 6-hydroxydopamine-induced rat model of Parkinson's disease［J］．Molecular Pain，2017，13：1744806917691525．DOI：10.1177/1744806917691525.
［66］CAO L F，PENG X Y，HUANG Y，et al．Restoring spinal noradrenergic inhibitory tone attenuates pain hypersensitivity in a rat model of Parkinson's disease［J］．Neural Plasticity，2016，2016：6383240．DOI：10.1155/2016/6383240.
［67］TONG Q，LI Z，YUAN Y S，et al．Reduced plasma serotonin and 5-hydroxyindoleacetic acid levels in Parkinson's disease are associated with nonmotor symptoms［J］．Parkinsonism & Related Disorders，2015，21（8）：882-887．DOI：10.1016/j.parkreldis.2015.05.016.
［68］DJALDETTI R，YUSTKATZ S，KOLIANOV V，et al．The effect of duloxetine on primary pain symptoms in Parkinson disease［J］．Clinical Neuropharmacology，2007，30（4）：201．DOI：10.1097/wnf.0b013e3180340319.
［69］BELLINGHAM G A，PENG P W.Duloxetine：a review of its pharmacology and use in chronic pain management［J］．Regional Anesthesia & Pain Medicine，2010，35（3）：294-303．DOI：10.1097/AAP.0b013e3181df2645.
［70］SANDYK R.Anticholinergic-induced analgesia：possible role for the cholinergic system in abnormal sensory symptoms in Parkinson's disease［J］．Postgraduate Medical Journal，1986，62（730）：749．DOI：10.1136/pgmj.62.730.749.
［71］CARDOSO F.Botulinum toxin in Parkinsonism：the when，how，and which for botulinum toxin injections［J］．Toxicon，2017，147（6）：107-110．DOI：10.1016/j.toxicon.2017.08.018.
［72］PACCHETTI C，ALBANI G，MARTIGNONI E，et al．Painful dystonia in Parkinson's disease treated with botulinum toxin［J］．Movement Disorders Official Journal of the Movement Disorder Society，1995，10（3）：333．DOI：10.1002/mds.870100317.
［73］TASSORELLI C，DE ICCO R，ALFONSI E，et al．Botulinum toxin type A potentiates the effect of neuromotor rehabilitation of pisa syndrome in Parkinson disease：a placebo controlled study［J］．Parkinsonism & Related Disorders，2014，20（11）：1140-1144．DOI：10.1016/j.parkreldis.2014.07.015.
［74］CORDIVARI C，MISRA V P，CATANIA S，et al．Treatment of dystonic clenched fist with botulinum toxin［J］．Movement Disorders Official Journal of the Movement Disorder Society，2001，16（5）：907-913．DOI：10.1002/mds.1186.
［75］GUPTA A D，VISVANATHAN R.Botulinum toxin for foot dystonia in patients with Parkinson's disease having deep brain stimulation：a case series and a pilot study［J］．Journal of Rehabilitation Medicine，2016，48（6）：559-562．DOI：10.2340/16501977-2094.
［76］BRUNO V A，FOX S H，MANCINI D，et al．Botulinum toxin use in refractory pain and other symptoms in Parkinsonism［J］．Canadian Journal of Neurological Sciences Le Journal Canadien Des Sciences Neurologiques，2016，43（5）：697．DOI：10.1017/cjn.2016.279.

[1]	TIAN Chen, LIU Jianing, TIAN Jinhui, GE Long. Living Systematic Reviews: Methods and Processes for Development [J]. Chinese General Practice, 2025, 28(30): 3853-3860.
[2]	WANG Tingting, TANG Yong, ZHANG Wenke, LI Zhigang. Research Progress on Exercise Intervention of Hyperuricemia [J]. Chinese General Practice, 2025, 28(30): 3841-3846.
[3]	BAI Jiaxin, CHEN Yu, ZHOU Yiheng, LIU Lidi, YANG Rong, YAO Yi, YUAN Bo, ZHANG Yonggang, LEI Yi, ZENG Rui, JIA Yu, LIAO Xiaoyang. Assessment and Treatment of Early-onset Hypertension: Position Statement of the British and Irish Hypertension Association and Its Implications for Clinical Management of Early-onset Hypertension in China [J]. Chinese General Practice, 2025, 28(30): 3741-3746.
[4]	XU Jialan, YAN Hong, WEN Jun, ZHOU Zitong, WANG Siyu. Prevalence of Potentially Inappropriate Medication in Older Adults with Cancer: a Meta-analysis [J]. Chinese General Practice, 2025, 28(30): 3815-3822.
[5]	LI Hao, LI Peijin, LIU Tingting, CUI Yiyuan, LI Sicong, LIU Lixing, FENG Li, Working Group on Integrated Traditional Chinese and Western Medicine Diagnosis and Treatment Guidelines for Cancer Pain. Guidelines on the Diagnosis and Treatment of Cancer Pain by Integrated Traditional Chinese and Western Medicine [J]. Chinese General Practice, 2025, 28(30): 3729-3740.
[6]	ZHOU Sheng, DENG Changsheng, ZOU Guanyang, SONG Jianping. Research Progress on the Pathogenesis of Complications of Malaria in Cardiovascular Diseases [J]. Chinese General Practice, 2025, 28(27): 3466-3472.
[7]	HUANG Yulin, WANG Haoyun, LI Yanmei, XIAO Xueying. Symptom Clusters in Gastric Cancer Patients Receiving Chemotherapy: a Scoping Review [J]. Chinese General Practice, 2025, 28(26): 3338-3344.
[8]	LIU Yinyin, SUI Hongping, LI Tingting, JIANG Tongtong, SHI Tieying, XIA Yunlong. Advances in Risk Prediction Models for Cardiotoxicity Associated with Breast Cancer Treatment [J]. Chinese General Practice, 2025, 28(24): 3072-3078.
[9]	LI Miaoxiu, ZHU Bowen, KONG Lingjun, FANG Min. Progress in Research on Clinical Assessment Tools for Conservative Treatment of Adolescent Idiopathic Scoliosis [J]. Chinese General Practice, 2025, 28(24): 3079-3088.
[10]	XIAO Yao, WAN Jun. Treatment of Venous Thromboembolism in Special Populations with Direct Oral Anticoagulants [J]. Chinese General Practice, 2025, 28(24): 3066-3071.
[11]	RUAN Wanbai, LI Junfeng, YIN Yanmei, PENG Lei, ZHU Kexiang. Research Progress of Targeted Therapy and Immunotherapy for Pancreatic Cancer [J]. Chinese General Practice, 2025, 28(23): 2950-2960.
[12]	ZHOU Lianpeng, LI Weifeng, DONG Xingang, WANG Xiaoyuan. Research Progress on the Role of Copper Homeostasis Regulation Mechanism in Cognition Disorder [J]. Chinese General Practice, 2025, 28(23): 2941-2949.
[13]	Chinese Hospital Association, Committee for Healthcare Simulation. Expert Consensus on the Application Technology System Standard of Virtual Simulation for Clinical Practice Skills [J]. Chinese General Practice, 2025, 28(23): 2833-2840.
[14]	DONG Haocheng, HAO Xiao, AN Dong, LI Haohan, LI Shuren. Research Progress of Heart Failure with Supra-normal Ejection Fraction [J]. Chinese General Practice, 2025, 28(21): 2692-2696.
[15]	DU Qiongliang, LIN Bailang, GUO Honghua. Research Progress and Implications of Group Well-child Care [J]. Chinese General Practice, 2025, 28(21): 2672-2678.